undamentalytics Newsletter
Sign in

Atara Biotherapeutics, Inc. balance sheet

At the end of fiscal 2025, Atara Biotherapeutics, Inc. had total assets of $20.2m, total liabilities of $58.7m and shareholders' equity of −$38.5m. It held $8.5m in cash against $0 of debt: net cash of $8.5m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents93262583
Receivables4034110
Inventory210110—
Total current assets295102651214
Total assets3761661092021
Accounts payable74401
Deferred revenue (current)—78———
Total current liabilities79142135157
Total debt00000
Total liabilities2502652065958
Shareholders' equity12799−97−39−37
Non-controlling interests and other (assets − liabilities − equity)—−198———
Net debt (negative = net cash)−93−26−25−8−3
Shares outstanding—4m———

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ATRA vs CGONATRA vs FATEATRA vs HCWB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Atara Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atara Biotherapeutics, Inc.